Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCMGlobeNewsWire • 10/17/24
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA SummitGlobeNewsWire • 06/18/24
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/24
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual MeetingGlobeNewsWire • 05/02/24
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/18/24
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications MedicineGlobeNewsWire • 03/18/24
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?Zacks Investment Research • 02/26/24
Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature CommunicationsGlobeNewsWire • 02/26/24
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a BetZacks Investment Research • 02/09/24
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's WhyZacks Investment Research • 01/26/24
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare ConferenceGlobeNewsWire • 11/21/23
Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyGlobeNewsWire • 10/26/23
Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific MeetingGlobeNewsWire • 10/09/23
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac RegenerationGlobeNewsWire • 10/02/23
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical ConferencesGlobeNewsWire • 09/21/23
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare ConferenceGlobeNewsWire • 08/31/23
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 08/09/23